What type of therapeutic drug does Teclistamab-cqyv belong to?

Teritusumab(Teclistamab-cqyv) is an innovative bispecificT cell-engaging antibody drug specifically used to treat multiple myeloma, especially relapsed or refractory cases that are resistant to standard treatments. This drug falls into the biological category of "immunotherapy drugs" and, more specifically, is a bispecific monoclonal antibody that targets CD3 and BCMA (B-cell maturation antigen).

BCMA is an antigen highly expressed on the surface of multiple myeloma cells, and CD3 is an important receptor on the surface of T cells. Through its double-antibody structure, teritusumab binds to BCMA on the surface of myeloma cells at one end and CD3 on the surface of T cells at the other end, thereby "bringing the two closer" and activating T cells. This mechanism can stimulate T cells to attack and kill target cells, achieving a precise immune response to tumors. It is different from traditional chemotherapy and targeted therapy and does not depend on the mutation background of the tumor. Therefore, it shows a better consistent efficacy in myeloma with strong tumor heterogeneity.

Different from CAR-T cell therapy, teritusumab is a "ready-made" immunotherapy that does not require personalized cells to be customized for each patient. Therefore, the treatment process is more standardized, shorter, and has wider applicability. Compared with traditional monoclonal antibodies such as daratumumab and isatolumab, teritusumab produces a stronger cytotoxic response through "dual target activation".

In addition, the administration method of teritusumab is also relatively convenient. It adopts subcutaneous injection and is administered once a week, which effectively avoids the inconvenience and discomfort caused by intravenous infusion and also reduces the risk of immune-related adverse reactions.

Therefore, teritusumab represents a new generation of immunotherapy today, which not only makes up for the shortcomings of traditional treatment methods, but also provides a practical new treatment option for patients with relapsed and refractory multiple myeloma.

Reference materials:https://www.tecvayli.com/